All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | Phase II study of blinatumomab in patients with B-ALL and positive MRD at a minimum threshold of ≥10−4

Sep 15, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

The ALL Hub is pleased to present a visual abstract of a phase II trial (NCT02458014) of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia with minimal residual disease of at least 104.



 

Visual Abstract

To download this visual abstract, click below.

Download here

Your opinion matters

What is your first choice when planning treatment for a patient with relapsed/refractory Philadelphia negative B-ALL with blast count >50%?
2 votes - 1 day left ...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox